Kazuma Sekiba

Kazuma Sekiba

Auto-generated profile, based on publicly available information

Kazuma Sekiba

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
KSKazuma Sekiba
Kazuma Sekiba
MOMotoyuki Otsuka
Motoyuki Otsuka
MOMotoko Ohno
Motoko Ohno
MYMari Yamagami
Mari Yamagami
TKTakahiro Kishikawa
Takahiro Kishikawa
KKKazuhiko Koike
Kazuhiko Koike
Hepatitis B virus (HBV) infection is a major health concern worldwide. Although currently used nucleos(t)ide analogs efficiently inhibit viral replication, viral proteins transcribed from the episomal viral covalently closed circular DNA (cccDNA) minichromosome continue to be expressed long-term. Because high viral RNA or antigen loads may play a biological role during this chronicity, the elimination of viral products is an ultimate goal of HBV treatment. HBV regulatory protein X (HBx) was recently found to promote transcription of cccDNA with degradation of Smc5/6 through the interaction of HBx with the host protein DDB1. Here, this protein-protein interaction was considered as a new molecular target of HBV treatment. To identify candidate compounds that target the HBx-DDB1 interaction, a newly constructed split luciferase assay system was applied to comprehensive compound screening. The effects of the identified compounds on HBV transcription and cccDNA maintenance were determined using HBV minicircle DNA, which mimics HBV cccDNA, and the natural HBV infection model of human primary hepatocytes. We show that nitazoxanide (NTZ), a thiazolide anti-infective agent that has been approved by the FDA for protozoan enteritis, efficiently inhibits the HBx-DDB1 protein interaction. NTZ significantly restores Smc5 protein levels and suppresses viral transcription and viral protein production in the HBV minicircle system and in human primary hepatocytes naturally infected with HBV. These results indicate that NTZ, which targets an HBV-related viral-host protein interaction, may be a promising new therapeutic agent and a step toward a functional HBV cure.

1 January 2022 in Journal of Hepatology
Verified
Journal Article
Open access
KSKazuma Sekiba
Kazuma Sekiba
MOMotoyuki Otsuka
Motoyuki Otsuka
KFKazuyoshi Funato
Kazuyoshi Funato
YMYu Miyakawa
Yu Miyakawa
ETEri Tanaka
Eri Tanaka
KKKazuhiko Koike
Kazuhiko Koike
HBV causes hepatocellular carcinoma (HCC). While it was recently shown that the ability of HBV X protein (HBx) to impair the Smc5/6 (structural maintenance of chromosome 5/6) complex is important for viral transcription, HBx is also a potent driver of HCC. However, the mechanism by which HBx expression induces hepatocarcinogenesis is unclear. Degradation of the Smc5/6 complex and accumulation of DNA damage were observed in both in vivo and in vitro HBV infection models. Rescue experiments were performed using nitazoxanide (NTZ), which inhibits degradation of the Smc5/6 complex by HBx. HBx-triggered degradation of the Smc5/6 complex causes impaired homologous recombination (HR) repair of DNA double-strand breaks (DSBs), leading to cellular transformation. We found that DNA damage accumulated in the liver tissue of HBV-infected humanized chimeric mice, HBx-transgenic mice, and human tissues. HBx suppressed the HR repair of DSBs, including that induced by the CRISPR-Cas9 system, in an Smc5/6-dependent manner, which was rescued by restoring the Smc5/6 complex. NTZ restored HR repair in, and colony formation by, HBx-expressing cells. Degradation of the Smc5/6 complex by HBx increases viral transcription and promotes cellular transformation by impairing HR repair of DSBs. The hepatitis B virus expresses a regulatory protein called HBV X protein (or HBx). This protein degrades the Smc5/6 complex in human hepatocytes, which is essential for viral replication. We found that this process also plays a key role in the accumulation of DNA damage, which contributes to HBx-mediated tumorigenesis.

26 December 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
KSKazuma Sekiba
Kazuma Sekiba
MOMotoyuki Otsuka
Motoyuki Otsuka
MOMotoko Ohno
Motoko Ohno
MYMari Yamagami
Mari Yamagami
TKTakahiro Kishikawa
Takahiro Kishikawa
KKKazuhiko Koike
Kazuhiko Koike

20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
KSKazuma Sekiba
Kazuma Sekiba
MOMotoyuki Otsuka
Motoyuki Otsuka
MOMotoko Ohno
Motoko Ohno
TKTakahiro Kishikawa
Takahiro Kishikawa
MYMari Yamagami
Mari Yamagami
KKKazuhiko Koike
Kazuhiko Koike
DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels

3 September 2020 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
TSTakahiro Seimiya
Takahiro Seimiya
MOMotoyuki Otsuka
Motoyuki Otsuka
TITakuma Iwata
Takuma Iwata
ETEri Tanaka
Eri Tanaka
KSKazuma Sekiba
Kazuma Sekiba
KKKazuhiko Koike
Kazuhiko Koike

8 April 2021 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
TSTatsunori Suzuki
Tatsunori Suzuki
TKTakahiro Kishikawa
Takahiro Kishikawa
TSTatsuyuki Sato
Tatsuyuki Sato
NTNorihiko Takeda
Norihiko Takeda
YSYuki Sugiura
Yuki Sugiura
KKKazuhiko Koike
Kazuhiko Koike
Mutational activation of the KRAS gene occurs in almost all pancreatic ductal adenocarcinoma (PDAC) and is the earliest molecular event in their carcinogenesis. Evidence has accumulated of the metabolic reprogramming in PDAC, such as amino acid homeostasis and autophagic flux. However, the biological effects of KRAS mutation on metabolic reprogramming at the earlier stages of PDAC carcinogenesis are unclear. Here we report dynamic metabolic reprogramming in immortalized human non-cancerous pancreatic ductal epithelial cells, in which a KRAS mutation was induced by gene-editing, which may mimic early pancreatic carcinogenesis. Similar to the cases of PDAC, KRAS gene mutation increased the dependency on glucose and glutamine for maintaining the intracellular redox balance. In addition, the intracellular levels of amino acids were significantly decreased because of active protein synthesis, and the cells required greater autophagic flux to maintain their viability. The lysosomal inhibitor chloroquine significantly inhibited cell proliferation. Therefore, metabolic reprogramming is an early event in carcinogenesis initiated by KRAS gene mutation, suggesting a rationale for the development of nutritional interventions that suppress or delay the development of PDAC.